Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.100
+0.020 (1.85%)
At close: Mar 20, 2026, 4:00 PM EDT
1.130
+0.030 (2.73%)
After-hours: Mar 20, 2026, 7:29 PM EDT
Fate Therapeutics Revenue
In the year 2025, Fate Therapeutics had annual revenue of $6.65M, down -51.24%. Fate Therapeutics had revenue of $1.37M in the quarter ending December 31, 2025, a decrease of -26.40%.
Revenue (ttm)
$6.65M
Revenue Growth
-51.24%
P/S Ratio
19.24
Revenue / Employee
$41,280
Employees
161
Market Cap
127.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.65M | -6.99M | -51.24% |
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
| Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
| Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
| Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
| Dec 31, 2015 | 2.43M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
| Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
| Dec 31, 2011 | 1.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 70.39M |
| Black Diamond Therapeutics | 70.00M |
| Sangamo Therapeutics | 32.88M |
| Innate Pharma | 14.84M |
| Equillium | 4.39M |
| Rani Therapeutics Holdings | 1.20M |
| Cardiff Oncology | 593.00K |
| Inovio Pharmaceuticals | 65.34K |
FATE News
- 17 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewsWire
- 4 months ago - Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewsWire
- 7 months ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 10 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire